BR112022000505A8 - Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc - Google Patents
Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qcInfo
- Publication number
- BR112022000505A8 BR112022000505A8 BR112022000505A BR112022000505A BR112022000505A8 BR 112022000505 A8 BR112022000505 A8 BR 112022000505A8 BR 112022000505 A BR112022000505 A BR 112022000505A BR 112022000505 A BR112022000505 A BR 112022000505A BR 112022000505 A8 BR112022000505 A8 BR 112022000505A8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- isoqc
- enzyme
- pyrrolidin
- fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185997 | 2019-07-12 | ||
| PCT/EP2020/069630 WO2021009068A1 (en) | 2019-07-12 | 2020-07-10 | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112022000505A2 BR112022000505A2 (pt) | 2022-03-22 |
| BR112022000505A8 true BR112022000505A8 (pt) | 2022-04-12 |
Family
ID=67262155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000505A BR112022000505A8 (pt) | 2019-07-12 | 2020-07-10 | Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230077723A1 (https=) |
| EP (1) | EP3997091A1 (https=) |
| JP (1) | JP2022542540A (https=) |
| KR (1) | KR20220054293A (https=) |
| CN (1) | CN114466849B (https=) |
| AU (1) | AU2020312647A1 (https=) |
| BR (1) | BR112022000505A8 (https=) |
| CA (1) | CA3147154A1 (https=) |
| IL (1) | IL289784A (https=) |
| MX (1) | MX2022000521A (https=) |
| PH (1) | PH12022550079A1 (https=) |
| WO (1) | WO2021009068A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3226468A1 (en) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Microbiocidal pyrazole derivatives |
| AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
| JP2024546927A (ja) | 2021-12-17 | 2024-12-26 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺微生物性ピラゾール誘導体 |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| PY2403614A (es) | 2023-01-27 | 2025-09-11 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| AR131665A1 (es) | 2023-02-01 | 2025-04-16 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| EP4455142A1 (en) | 2023-04-26 | 2024-10-30 | Scenic Immunology B.V. | Novel inhibitor of qpctl and/or qc |
| PY2447478A (es) | 2023-06-14 | 2025-03-18 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025163143A1 (en) | 2024-02-02 | 2025-08-07 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102186475B (zh) * | 2008-09-04 | 2016-08-03 | 前体生物药物股份公司 | 新抑制剂 |
| US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| MX2015016421A (es) * | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| EP3747438A1 (en) * | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
-
2020
- 2020-07-10 MX MX2022000521A patent/MX2022000521A/es unknown
- 2020-07-10 CA CA3147154A patent/CA3147154A1/en active Pending
- 2020-07-10 PH PH1/2022/550079A patent/PH12022550079A1/en unknown
- 2020-07-10 EP EP20743091.9A patent/EP3997091A1/en active Pending
- 2020-07-10 AU AU2020312647A patent/AU2020312647A1/en not_active Abandoned
- 2020-07-10 US US17/626,614 patent/US20230077723A1/en not_active Abandoned
- 2020-07-10 BR BR112022000505A patent/BR112022000505A8/pt unknown
- 2020-07-10 KR KR1020227004600A patent/KR20220054293A/ko not_active Ceased
- 2020-07-10 JP JP2022501167A patent/JP2022542540A/ja active Pending
- 2020-07-10 WO PCT/EP2020/069630 patent/WO2021009068A1/en not_active Ceased
- 2020-07-10 CN CN202080056962.2A patent/CN114466849B/zh active Active
-
2022
- 2022-01-12 IL IL289784A patent/IL289784A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230077723A1 (en) | 2023-03-16 |
| JP2022542540A (ja) | 2022-10-05 |
| PH12022550079A1 (en) | 2023-04-12 |
| CN114466849A (zh) | 2022-05-10 |
| IL289784A (en) | 2022-03-01 |
| BR112022000505A2 (pt) | 2022-03-22 |
| MX2022000521A (es) | 2022-06-14 |
| CA3147154A1 (en) | 2021-01-21 |
| WO2021009068A1 (en) | 2021-01-21 |
| KR20220054293A (ko) | 2022-05-02 |
| EP3997091A1 (en) | 2022-05-18 |
| AU2020312647A1 (en) | 2022-02-24 |
| CN114466849B (zh) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000505A8 (pt) | Compostos de 3,4-(anel fundido em 5)-5-fenil-pirrolidin-2-ona n-substituídos como inibidores de enzima isoqc e/ou qc | |
| CU20210065A7 (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2 | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| AU2013311573A8 (en) | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | |
| EP4520328A3 (en) | Heterocyclic compounds as immunomodulators | |
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MY197635A (en) | Benzooxazole derivatives as immunomodulators | |
| MY199220A (en) | Heterocyclic compounds as immunomodulators | |
| MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
| PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| BR112013026494A2 (pt) | composto, composição farmacêutica, método para tratar condição | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| MY209771A (en) | Compounds for use in the treatment of fascioliasis | |
| MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
| MY187891A (en) | Tetrahydropyridine derivatives as fabi inhibitors | |
| WO2022106984A3 (en) | Small molecule inhibitors of sars-cov2 main protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |